Anika Therapeutics | ANIK - Current Assets


Anika Therapeutics reported $99.19M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Agenus USD 78.81M 16.47M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Insmed USD 1.63B 20.75M Jun/2026
Integra LifeSciences USD 1.19B 19.46M Jun/2026
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 59.77B 601M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 1.46B 591.7M Jun/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merit Medical Systems USD 1.11B 10.46M Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 31.52B 1.36B Jun/2026
Smith & Nephew USD 4.39B 240M Jun/2026
Stryker USD 14.42B 1.08B Jun/2026
Veracyte USD 574.78M 52.6M Jun/2026
Xencor USD 523.21M 40.36M Jun/2026
Zimmer Biomet Holdings USD 5.1B 134.2M Jun/2026